[¹⁸F]MC225 PET Analysis of Blood–Brain Barrier Function in Glioblastomas
Key facts
- Where
- Groningen, HollandiaSee the site
- Phase
- 1. fázis
Where in Hollandia
- UMCGGroningen, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Medisch Centrum Groningen
- Trial code
- EU 2026-526106-32-00
- Record updated
- 2026. szeptember 28.
- Original description
To quantify [¹⁸F]MC225 tracer kinetics as a measure of P-glycoprotein function at the blood–brain barrier in tumor and peritumoral regions of patients with radiological suspicion of glioblastoma.Read full original descriptionShow less
To quantify [¹⁸F]MC225 tracer kinetics as a measure of P-glycoprotein function at the blood–brain barrier in tumor and peritumoral regions of patients with radiological suspicion of glioblastoma.
Inclusion: Age 18 years or older; Radiological suspicion of glioblastoma; Candidate for tumor reductive surgery; Predominantly unilateral tumor suitable for regional imaging analysis; Eligible for contrast-enhanced MRI according to routine clinical safety screening; Able to undergo PET imaging, arterial and venous blood sampling according to the study protocol; Able to understand study information and provide written informed consent; Imaging procedures can be performed within 14 days prior to surgery without delaying standard clinical care.
Exclusion: Use of medications known to significantly affect P-glycoprotein function, unless these can be safely discontinued prior to imaging; Contraindications to study procedures, including PET and MRI imaging, arterial or venous catheterisation, MRI, or administration of gadolinium-based contrast agents (e.g., non-MRI-compatible implants, severe contrast allergy, or impaired renal function); Relevant neurological or psychiatric conditions that may interfere with study participation, imaging quality, or interpretation of results, at the discretion of the investigator; Pregnancy or breastfeeding; Inability to provide informed consent; Extensive bilateral tumor involvement precluding regional analysis.